

7-8
MAY

Le Meridien
Cambridge Boston
Le MERIDIEN



VENTURE CAPITAL & PRIVATE EQUITY

STRATEGY MEETING EAST COAST USA **2025**

*Investment Challenges and Opportunities
in Emerging Biotech Markets*

Featuring Industry Leaders and Decision Makers



Doug Zingale
Managing Partner
Blue Goose Capital



David Sherris
CEO
**Attivare
Therapeutics**



Robert Gabriel
Board Member,
Managing Partner
Ashur Capital



**Claire Elizabeth
Smith**
Partner
**SpringTide
Ventures**



**Tomasz H.
Zastawny,
PhD, DSc**
Strategic Advisor
Auxilius Pharma



What Makes
Our Strategy
Meetings
So Unique?

CHECK OUT OUR
**STRATEGY
MEETING**

Facilitator Faculty


VENTURE CAPITAL &
PRIVATE EQUITY
BOSTON 2025

7-8
MAY



Claire Elizabeth Smith
Partner
SpringTide Ventures



Caitlyn Harvey
Vice President,
Head of CMC
**Convergent
Therapeutics, Inc.**



Doug Zingale
Managing Partner
Blue Goose Capital



David Sherris
CEO
**Attivare
Therapeutics**



Gregory Papastoitsis
Chief Process and
Manufacturing Officer
Ankyra Therapeutics



Gopi Vudathala
Global Head, Regulatory
Affairs CMC
Incyte Corporation



**Tomasz H.
Zastawny,
PhD, DSc**
Strategic Advisor
Auxilius Pharma
CEO
Armora Biosciences



Stephan Krause
Executive Director, Cell
Therapy Global Quality
Bristol Myers Squibb



Robert Gabriel
Board Member,
Managing Partner
Ashur Capital

*Intimate format
events where senior
leadership discuss the
biggest challenges
facing the industry.*



How it Works?

Real insights are shared in conversations, not lectures. That's why our unique **roundtable** format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Simply follow the steps below to select your roundtable discussions and we'll create your own personalised agenda for the day:

01

EXPLORE THE FULL AGENDA

Select which roundtable discussions you would like to join. Our sessions are divided among 6 themed tracks for easy selection - you can choose to join any session you like.

02

COMPLETE YOUR SCHEDULING FORM

Select your preferred roundtable discussion for each time slot. We will send this form out via email a few weeks before the event - be sure to get your first choice by completing the form quickly.

03

ENJOY YOUR PERSONALISED EXPERIENCE











Join your selected roundtable sessions on the day. We will give you your personalised agenda containing the time and room assignments of your chosen roundtable discussions so you won't miss it.

Agenda at a Glance

Venture Capital & Private Equity Overview 7th & 8th of May, 2025 – Cambridge, Boston - Le Meridien Hotel

DAY 1

DAY 2

TIME EST	INVESTMENT IN CLINICAL TRIALS & MANUFACTURING	INVESTMENT IN DRUG DISCOVERY & BIOTECH
ROOM~	Robert R Taylor	Robert R Taylor
08:00 - 08:30	REGISTRATION AND WELCOME	
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: Managing a Complex Global Network for Internal and External QC Testing for Autologous Cell Therapies  Stephan Krause, Executive Director, Cell Therapy Global Quality, Bristol Myers Squibb	OPENING KEYNOTE PRESENTATION: Scaling Biotech Ventures: Challenges and Opportunities for Investors in Drug Discovery Startups
09:00 - 10:00	Balancing Cost-Effectiveness with Data Reliability in Decentralized Models	What Are the Emerging Trends in Venture Capital for Drug Discovery and Biotech Startups?  David Sherris, CEO, Attivare Therapeutics
10:00 - 10:05	REFRESHMENT BREAK	
10:05 - 10:25	NETWORKING / 1-1 MEETINGS	
10:25 - 10:45	NETWORKING / 1-1 MEETINGS	
10:45 - 11:05	NETWORKING / 1-1 MEETINGS	
11:10 - 12:10	Can the Boom and Bust Cycle of Biotech Investing be Changed?  Doug Zingale, Managing Partner, Blue Goose Capital	2025 Investment Trends: Transforming Drug Discovery Ventures
12:15 - 1:15	Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?  Robert Gabriel, Board Member, Managing Partner, Ashur Capital	Scaling Biotech Ventures: Challenges and Opportunities for Investors in Life Science Startup  Tomasz H. Zastawny, PhD, DSc, Strategic Advisor, Auxilius Pharma CEO, Armora Biosciences
13:15 - 14:00	NETWORKING LUNCH	
14:00 - 14:20	NETWORKING / 1-1 MEETINGS	
14:20 - 14:40	NETWORKING / 1-1 MEETINGS	
14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION	
15:10 - 16:10	Global Expansion of Clinical Trials: Opportunities and Challenges	Investment Challenges and Opportunities in Emerging Biotech Markets  Claire Elizabeth Smith, Partner, SpringTide Ventures
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK	
16:30 - 17:00	PANEL DISCUSSION: What Do Investors and Partners Consider the "Must-Have" Value Drivers for CMC in a New Modality?  CHAIRPERSON: Caitlyn Harvey, Vice President, Head of CMC, Convergent Therapeutics, Inc.  PANELIST: Robert Gabriel, Board Member, Managing Partner, Ashur Capital  PANELIST: Gregory Papastoitsis, Chief Process and Manufacturing Officer, Ankyra Therapeutics  PANELIST: Gopi Vudathala, Global Head, Regulatory Affairs CMC, Incyte Corporation	PANEL DISCUSSION: Venture Strategies for Biotech Startups: Building Scalable Innovations in Drug Discovery
17:00 - 18:00	DRINKS & CANAPES RECEPTION	

Event Day

DAY 1: Investment in Clinical Trials & Manufacturing


**VENTURE CAPITAL &
PRIVATE EQUITY**
BOSTON 2025

**7-8
MAY**

 **08:00 - 08:30 ET** **REGISTRATION & WELCOMING**

 **08:30 - 09:00 ET** **OPENING PANEL DISCUSSION**

Managing a Complex Global Network for Internal and External QC Testing for Autologous Cell Therapies



Stephan Krause

Executive Director, Cell Therapy Global Quality
Bristol Myers Squibb

ABOUT THE SPEAKER

Speaker TBC

 **09:00 - 10:00 ET** **ROUNDTABLE 1**

Balancing Cost-Effectiveness with Data Reliability in Decentralized Models (Topic TBC)




Speaker TBC

ABOUT THE SPEAKER

Speaker TBC

 **10:00 - 11:05 ET** **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

 **11:10 - 12:10 ET** **ROUNDTABLE 2**

Can the Boom and Bust Cycle of Biotech Investing be Changed?




Doug Zingale

Managing Partner
Blue Goose Capital

ABOUT THE SPEAKER

Doug has been involved with the biotech industry since the Biogen IPO and has worked on transactions with Biogen, Vertex and many start-ups, investment banks and venture capital firms. For the last 7 years, Doug has been the Managing Partner of Blue Goose Capital, a venture fund making Seed, Series A and Series B investments in biotech, medical device and digital health companies in the US and Spain. Biotech investments include Mythic Therapeutics, Therini Bio and AtG.

 **12:15 - 13:15 ET** **ROUNDTABLE 3**

Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?



- Optimizing trial design
- Leveraging technology
- Enhancing patient recruitment
- Streamlining processes



Robert Gabriel

Board Member, Managing Partner
Ashur Capital

ABOUT THE SPEAKER

Dr. Robert Gabriel has broad experience in technology and business development. He founded Genesis Aromatique and led the company for over 15 years. Prior to that, Gabriel led technology and business development initiatives at Unilever, Gillette, Clorox, and Rhone-Poulenc. In his current role as Ashur Capital's managing partner and board member, Dr. Gabriel provides strategic direction for asset allocation and capital deployment. He is also an investor and board member at Clear Protocol, a digital health startup. Dr. Gabriel earned a Ph.D. from the University of Illinois and an MBA from the Wharton School of Business. Dr. Gabriel is married and has 4 sons.

 **13:15 - 14:40 ET** **NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS**

 **14:40 - 15:10 ET** **AFTERNOON KEYNOTE PRESENTATION**

Topic TBC



Speaker TBC

ABOUT THE SPEAKER

Speaker TBC

 **15:10 - 16:10 ET** **ROUNDTABLE 4**

Global Expansion of Clinical Trials: Opportunities and Challenges




Speaker TBC

ABOUT THE SPEAKER

Speaker TBC

 **16:10 - 16:30 ET** **AFTERNOON REFRESHMENT BREAK**

 **16:30 - 17:00 ET** **PANEL DISCUSSION**

What Do Investors and Partners Consider the "Must-Have" Value Drivers for CMC in a New Modality?



Caitlyn Harvey

Vice President, Head of CMC
Convergent Therapeutics, Inc.

ABOUT THE SPEAKER

Speaker TBC

 **17:00 - 18:00 ET** **DRINKS & CANAPES RECEPTION**

Event Day

DAY 2: Investment in Drug Discovery & Biotech

08:00 - 08:30 ET REGISTRATION & WELCOMING

ABOUT THE SPEAKER
Speaker TBC

08:30 - 09:00 ET OPENING PANEL DISCUSSION

Scaling Biotech Ventures: Challenges and Opportunities for Investors in Drug Discovery Startups



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

09:00 - 10:00 ET ROUNDTABLE 1

What Are the Emerging Trends in Venture Capital for Drug Discovery and Biotech Startups?



- Fund raising in the Trump administration, opportunities with venture capitalists, investment banks and angels



David Sherris
CEO
Attivare Therapeutics

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:05 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET ROUNDTABLE 2

2025 Investment Trends: Transforming Drug Discovery Ventures



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 ET ROUNDTABLE 3

Scaling Biotech Ventures: Challenges and Opportunities for Investors in Life Science Startup



Tomasz H. Zastawny, PhD, DSc
Strategic Advisor at Auxilius Pharma
CEO at Armora Biosciences

- The Current Investment Climate
- Re-evaluating R&D Pipelines and Investment Strategies
- Opportunities in Modern Biotech
- Navigating the Scaling Journey

13:15 - 14:40 ET NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 ET AFTERNOON KEYNOTE PRESENTATION

Topic TBC



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

15:10 - 16:10 ET ROUNDTABLE 4

Investment Challenges and Opportunities in Emerging Biotech Markets



Claire Elizabeth Smith
Partner
SpringTide Ventures

ABOUT THE SPEAKER

Claire is a partner at SpringTide and has spent her career focused at the intersection of healthcare, life sciences, and business. Prior to SpringTide, she was an investor at Meridian Street Capital, where she focused on seed-stage health tech, and Anterra Capital, where she focused agriculture biotech while launching several animal health startups. She was previously the Chief of Staff at Crestovo, a microbiome therapeutics startup acquired by Finch Therapeutics. She began her career at ClearView Healthcare Partners, a boutique strategy consultancy serving the pharma and biotech industry. Claire holds bachelor's degrees in biological engineering and management science from MIT.

16:10 - 16:30 ET AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 ET PANEL DISCUSSION

Venture Strategies for Biotech Startups: Building Scalable Innovations in Drug Discovery



Speaker TBC

ABOUT THE SPEAKER

17:00 - 18:00 ET DRINKS & CANAPES RECEPTION

Venue

Le Meridien Hotel - Cambridge, Boston

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort.

[HOTEL DETAILS →](#)

[MAP & DIRECTIONS →](#)

Le **MERIDIEN**


OUR FACE-TO-FACE MEETING IN MAY & NOVEMBER 2025


Strategy Meeting Boston, Princeton & San Diego

MAY

Boston/Cambridge MA - US East Coast

- MAY**
7
WED

 **CHEMISTRY MANUFACTURING CONTROL**
CMC Strategy Meeting 2025
📍 Le Meridien Boston Cambridge
- MAY**
8
THUR

 **MEDICINAL CHEMISTRY**
Medicinal Chemistry Strategy Meeting 2025
📍 Le Meridien Boston Cambridge

- MAY**
7-8
WED&THUR

 **VENTURE CAPITAL
PRIVATE EQUITY**
Venture Capital & Private Equity
📍 Le Meridien Boston Cambridge

Princeton/New Jersey - US East Coast

- MAY**
14
WED

 **MEDICINAL CHEMISTRY**
Medicinal Chemistry Strategy Meeting 2025
📍 Hyatt Regency Princeton
- MAY**
15
THUR

 **CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
**Clinical Operations & Clinical Trial Supply Chain
Strategy Meeting 2025**
📍 Hyatt Regency Princeton
- MAY**
14-15
WED&THUR

 **VENTURE CAPITAL
PRIVATE EQUITY**
Venture Capital & Private Equity
📍 Hyatt Regency Princeton

OCTOBER

London/UK - Europe

- OCT**
9
THUR

 **CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
**Clinical Operations & Clinical Trial Supply Chain
Strategy Meeting 2025**
📍 Crowne Plaza, London Docklands
- OCT**
16
THUR

 **MEDICINAL CHEMISTRY**
Medicinal Chemistry Strategy Meeting 2025
📍 Crowne Plaza, London Docklands
- OCT**
15
WED

 **BIOINFORMATICS & DRUG DISCOVERY BIOLOGY**
Bioinformatics & Drug Discovery Biology Strategy Meeting 2025
📍 Crowne Plaza, London Docklands

NOVEMBER

San Diego - US West Coast

- NOV**
12
WED

 **MEDICINAL CHEMISTRY**
Medicinal Chemistry Strategy Meeting 2025
📍 Hard Rock Hotel San Diego
- NOV**
13
THUR

 **CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
**Clinical Operations & Clinical Trial Supply Chain
Strategy Meeting 2025**
📍 Hard Rock Hotel San Diego

Boston/Cambridge MA - US East Coast

- NOV**
18
TUE

 **CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
**Clinical Operations & Clinical Trial Supply Chain
Strategy Meeting 2025**
📍 Le Meridien Boston Cambridge
- NOV**
19
WED

 **BIOINFORMATICS &
DRUG DISCOVERY BIOLOGY**
**Bioinformatics & Drug Discovery Biology
Strategy Meeting 2025**
📍 Le Meridien Boston Cambridge